Poseida Therapeutics (PSTX) News Today → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free PSTX Stock Alerts $3.20 +0.12 (+3.90%) (As of 12:39 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePoseida Therapeutics, Inc.: Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officerfinanznachrichten.de - March 26 at 7:29 AMPoseida Therapeutics appoints Syed Rizvi as Chief Medical Officermsn.com - March 26 at 7:29 AMPoseida Therapeutics (NASDAQ:PSTX) Trading Down 2.3%americanbankingnews.com - March 26 at 3:08 AMPoseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officerfinance.yahoo.com - March 25 at 4:19 PMPoseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conferencefinance.yahoo.com - March 19 at 5:12 PMPSTX Apr 2024 5.000 putfinance.yahoo.com - March 15 at 11:16 PMPoseida Therapeutics, Inc.: Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myelomafinanznachrichten.de - March 15 at 8:14 AMPoseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myelomafinance.yahoo.com - March 13 at 6:31 PMPoseida spikes after FDA orphan status for CAR-T therapymsn.com - March 13 at 8:30 AMEQT, Genie Energy And Other Big Stocks Moving Lower On Mondaymsn.com - March 11 at 1:56 PMUS$14.00 - That's What Analysts Think Poseida Therapeutics, Inc. (NASDAQ:PSTX) Is Worth After These Resultsfinance.yahoo.com - March 10 at 2:22 PMPoseida Therapeutics Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - March 9 at 8:46 AMBuy Rating for Poseida Therapeutics Amid Strong Financials and Promising Clinical Updatesmarkets.businessinsider.com - March 8 at 2:56 PMAnalysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)markets.businessinsider.com - March 8 at 2:56 PMPoseida Therapeutics Inc (PSTX) Reports Fourth Quarter and Full Year 2023 Financial Resultsfinance.yahoo.com - March 8 at 12:28 AMPSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 8 at 12:16 AMPoseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023finance.yahoo.com - March 7 at 7:17 PMPoseida Therapeutics, Inc.: Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)finanznachrichten.de - March 6 at 4:25 PMPoseida Therapeutics Inc Ordinary Sharesmorningstar.com - March 1 at 8:16 PMInstitutional investors own a significant stake of 41% in Poseida Therapeutics, Inc. (NASDAQ:PSTX)finance.yahoo.com - February 27 at 7:44 AMAcadian Asset Management LLC Decreases Stock Holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX)marketbeat.com - February 27 at 6:01 AMPoseida Therapeutics, Inc. (NASDAQ:PSTX) Stock Position Increased by Silverarc Capital Management LLCmarketbeat.com - February 18 at 12:53 PMBlair William & Co. IL Buys 171,910 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX)marketbeat.com - February 17 at 7:24 AMPoseida Therapeutics Stock (NASDAQ:PSTX) Insider Tradesbenzinga.com - February 2 at 8:02 PMPoseida Therapeutics Stock (NASDAQ:PSTX) Dividends: History, Yield and Datesbenzinga.com - February 2 at 8:02 PMBTIG Keeps Their Buy Rating on Poseida Therapeutics (PSTX)markets.businessinsider.com - January 8 at 1:07 AMPoseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestonesfinance.yahoo.com - January 4 at 12:48 PMBTIG Reaffirms Their Buy Rating on Poseida Therapeutics (PSTX)markets.businessinsider.com - January 3 at 5:49 AMBarclays PLC Has $57,000 Stock Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX)marketbeat.com - December 28 at 4:02 AMBuy Rating Affirmed for Poseida Therapeutics Amid Positive P-BCMA-ALLO1 Program Findingsmarkets.businessinsider.com - December 23 at 10:17 AMPoseida Therapeutics: Non-Self CAR T Looks To Be Safe And Potentially Impactfulseekingalpha.com - December 21 at 9:47 AMPoseida Therapeutics, Inc. (NASDAQ:PSTX) Short Interest Updatemarketbeat.com - December 16 at 9:52 PMPoseida Therapeutics (PSTX) Price Target Increased by 14.29% to 14.28msn.com - December 16 at 6:40 PMHC Wainwright Research Analysts Boost Earnings Estimates for Poseida Therapeutics, Inc. (NASDAQ:PSTX)marketbeat.com - December 13 at 7:45 AMPoseida Therapeutics: Strong Buy on Promising CAR-T Therapy and Strategic Roche Partnershipmarkets.businessinsider.com - December 12 at 6:20 PMBYND, MAT and ARCT are among after hour moversseekingalpha.com - December 12 at 8:19 AMBuy Rating on Poseida Therapeutics Amid Promising Clinical Data and Robust Pipeline Potentialmarkets.businessinsider.com - December 12 at 12:30 AMAnalysts Offer Insights on Healthcare Companies: Cigna (CI) and Poseida Therapeutics (PSTX)markets.businessinsider.com - December 11 at 7:30 PMPoseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatmentmarketwatch.com - December 11 at 2:30 PMPoseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trialmarkets.businessinsider.com - December 11 at 2:30 PMPoseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meetingfinance.yahoo.com - December 10 at 1:21 PMBiotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcarefinance.yahoo.com - November 25 at 9:43 AMPiper Sandler Reaffirms Their Buy Rating on Poseida Therapeutics (PSTX)markets.businessinsider.com - November 11 at 9:24 AMAnalysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Poseida Therapeutics (PSTX)markets.businessinsider.com - November 10 at 2:22 PMPoseida Therapeutics, Inc.: Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023finanznachrichten.de - November 10 at 9:22 AMPoseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023finance.yahoo.com - November 9 at 7:21 PMPoseida Therapeutics to Present at the 65th ASH Annual Meeting and Expositionfinance.yahoo.com - November 2 at 10:14 AMPoseida Therapeutics (PSTX) Receives Buy Rating: Leadership Change, Strategic Partnerships, and Promising Clinical Trials Drive Optimistic Outlookmarkets.businessinsider.com - October 20 at 10:13 AMAll You Need to Know About Poseida Therapeutics, Inc. (PSTX) Rating Upgrade to Buyfinance.yahoo.com - October 16 at 3:24 PMPoseida Therapeutics Announces Leadership Transitionfinance.yahoo.com - October 9 at 6:52 PM Get Poseida Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Urgent: Protect Your Investments from a Chinese Invasion (Ad)An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion. Click here to get my exclusive report NOW >>> PSTX Media Mentions By Week PSTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTX News Sentiment▼0.190.60▲Average Medical News Sentiment PSTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTX Articles This Week▼51▲PSTX Articles Average Week Get Poseida Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KOD News Today OCGN News Today AURA News Today CHRS News Today CMPX News Today GRTS News Today SLDB News Today FENC News Today SOPH News Today TNYA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poseida Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.